NOVEMBER 20216Managing EditorAlex D'SouzaSalesAndrew D'Souzaandrew.dsouza@medicaltechoutlook.comEmailsales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comCopyright © 2021 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffNovember 01, 2021 volume 05 - Issue 11 (ISSN 2691-4093) Published by ValleyMedia, Inc. To subscribe to MedicalTech OutlookVisit www.medicaltechoutlook.com Alex D'SouzaManaging Editoreditor@medicaltechoutlook.comWhen Willelm Kolff and Belding Scribner introduced dialysis for the first time, it was considered a major breakthrough in the world of nephrology and urology medicine. Today, with a plethora of advances in kidney biology, kidney cell differentiation protocols, and stem cells, biomaterials, sensors, sorbents and engineering, nanotechnology, and interdisciplinary approaches and collaborations are poised to make way for disruptive innovation. Banking on technological developments and growing clinical evaluation of the target disease indications, the realm of nephrology and urology is ripe for remarkable strides.Many new solutions have come along in diagnosing, treating, and managing kidney disorders like chronic kidney disease (CKD)--one of the most striking trends driving the evolution of the demand in the market. Thanks to genome-wide association study of membranous nephropathy, the positions of novel loci can be easily identified within the kidney structures. In addition, upon integrating this data with the metabolomic information from patients suffering from chronic kidney disease, clinicians can easily cure metabolite infections. Furthermore, the infusion of therapeutic approaches for the treatment of anti-neutrophil cytoplastic auto-antibody has opened new doors in the world of nephrology medicine. Standing at the cusp of these innovations, there are a wide range of companies that offer the latest methods best suited for the next generation of kidney treatment needs. To help leaders navigate through the list of nephrology solution options, our panel comprising industry experts and the editorial board of MedTech Outlook has narrowed down the top companies in this landscape that exhibit competence in delivering robust nephrology approaches. Equipped with innovative technological capabilities, these enlisted companies are transforming the nephrology and urology realm at the cloverleaf of various disruptive technologies. We hope this issue of MedTech Outlook helps you build the partnership you and your organization need to foster an environment driven by robust and efficient technology. Let us know your thoughts!Paving the Way for Smart Nephrology TreatmentsEditorial StaffJoshua Parker Merlin WatsonJoe Philip Laura PintoSarah FernandesEDITORIALVisualizerRonald DonovanEthan Adam
< Page 5 | Page 7 >